Eucrates Biomedical Acquisition Corp.
NASDAQ: EUCR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Financial Services
- Industry
- Shell Companies
- CEO
- Parag Phoolchand Saxena MBA, MS
- Headquarters
- New York City, United States
- IPO year
- 2020
- Market cap
- $42.2M
Loading EUCR…
Loading profile data…Frequently asked questions about EUCR
What does Eucrates Biomedical Acquisition Corp. (EUCR) do?
Eucrates Biomedical Acquisition Corp. currently lacks substantial business operations. Its primary objective is to execute a corporate transaction such as a merger, stock swap, asset purchase, equity acquisition, restructuring, or another comparable strategic alliance involving one or more enterprises. Specifically, it aims to find and acquire a...
Where does EUCR trade?
Eucrates Biomedical Acquisition Corp. (EUCR) trades on the NASDAQ Capital Market.
What sector is EUCR in?
Eucrates Biomedical Acquisition Corp. (EUCR) operates in the Financial Services sector, specifically in the Shell Companies industry.
Who is the CEO of Eucrates Biomedical Acquisition Corp.?
Parag Phoolchand Saxena MBA, MS is the chief executive officer of Eucrates Biomedical Acquisition Corp. (EUCR).
Where is Eucrates Biomedical Acquisition Corp. headquartered?
Eucrates Biomedical Acquisition Corp. is headquartered in United States.
Does EUCR pay a dividend?
Eucrates Biomedical Acquisition Corp. (EUCR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EUCR go public?
Eucrates Biomedical Acquisition Corp. (EUCR) completed its initial public offering in 2020.